FDA accepts AstraZeneca's fish oil-based drug Epanova for review

09/19/2013 | Reuters · PharmaTimes (U.K.)

The FDA has accepted AstraZeneca's application to market its fish oil-based drug Epanova as a treatment for severe hypertriglyceridemia. The drug was originally developed by Omthera Pharmaceuticals, which was bought by AstraZeneca this year. A decision is expected by May 5.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA